Grove Biopharma, a Chicago-based startup, has closed a $30 million Series A funding round, falling short of its $50 million target. The company aims to develop a novel biologics platform called Bionic Biologics™, designed to target intracellular diseases, with an initial focus on treating aggressive prostate cancers. The funding round was led by DCVC funds, with participation from Eli Lilly and Company. Concurrently, the U.S. Food and Drug Administration (FDA) is considering a conditional approval pathway for rare disease drugs based on a plausible mechanism of action, which could allow gene editing startups to bring products to market prior to Phase 3 trials without randomized controlled trials or lengthy waits. This pathway is being discussed as a potential regulatory innovation to accelerate treatments for rare diseases. In parallel, advances in gene editing and biotechnology continue, including machine learning-engineered bespoke SpCas9 enzymes that outperform traditional nucleases, and HuidaGene initiating three first-in-human trials with compact, high-fidelity CRISPR editors. Additionally, research into longevity is progressing, with startups like Matter Bio studying long-lived animals and humans to uncover genetic secrets for gene therapy development. The science of aging is advancing rapidly, with new molecular clocks and single-cell multi-modal foundation models enhancing understanding of gene regulation and transcriptomic changes. Other notable developments include novel computational tools for RNA sequencing analysis and improved CRISPR off-target prediction models integrating epigenetic features. These innovations collectively signify a dynamic period in biotech, driven by regulatory shifts, funding activity, and technological breakthroughs.